½ÃÀ庸°í¼­
»óǰÄÚµå
1443393

¼¼°èÀÇ ¹é¹ÝÁõ Ä¡·á ½ÃÀå ±Ô¸ð Á¶»ç ¹× ¿¹Ãø : À¯Çüº°, À¯Åë ä³Îº°, ¾àÁ¦ Ŭ·¡½ºº°, Áö¿ªº° ºÐ¼®(2023-2030³â)

Global Vitiligo Treatment Market Size study & Forecast, by Type, by Distribution Channel, by Drug Class Type and Regional Analysis, 2023-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ¹é¹ÝÁõ Ä¡·á ½ÃÀåÀº 2022³â¿¡ ¾à 4¾ï 4,656¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, ¿¹Ãø ±â°£2023-2030³â¿¡´Â 4.3% ÀÌ»óÀÇ °ÇÀüÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

¹é¹ÝÁõÀº »ö¼Ò¸¦ »ý¼ºÇÏ´Â ¼¼Æ÷(¸á¶ó´Ñ ¼¼Æ÷)°¡ ¼Ò½ÇµÇ¾î ÇǺο¡ Èò ¹ÝÁ¡ÀÌ »ý±â´Â ÇǺΠÁúȯÀÔ´Ï´Ù. ÇöÀç ½É»ó¼º ¹é¹ÝÁõÀ» Ä¡·áÇÒ ¼ö ÀÖ´Â ¹æ¹ýÀº ¾øÁö¸¸, ´Ù¾çÇÑ Ä¡·á¹ýÀÌ ÀÌ ÁúȯÀ» °ü¸®Çϰí ÅëÁ¦ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. Ä¡·á ¹æ¹ýÀÇ ¼±ÅÃÀº »ö¼Ò Å»»ö Á¤µµ, ȯÀÚÀÇ ³ªÀÌ, Àü½Å °Ç°­ »óÅ ¹× ±âŸ ¿äÀο¡ µû¶ó ´Þ¶óÁý´Ï´Ù. ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ½É»ó¼º ¹é¹ÝÁõÀÇ À¯º´·ü Áõ°¡, ¹Ì¿ë Ä¡·á¿¡ ´ëÇÑ È¯ÀÚ ¼ö¿ä Áõ°¡, ½É»ó¼º ¹é¹ÝÁõ°ú »ç¿ë °¡´ÉÇÑ Ä¡·á¹ý¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡·Î 2023-2030³âÀÇ ¿¹Ãø ±â°£ Áß ½ÃÀå¿¡ À¯¸®ÇÑ ¼ö¿ä¸¦ âÃâÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¶ÇÇÑ Àü ¼¼°è¿¡¼­ ¹é¹ÝÁõ À¯º´·üÀÌ Áõ°¡Çϸ鼭 È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Journal of the American Academy of Dermatology¿¡ µû¸£¸é ¹é¹ÝÁõÀÇ Àü ¼¼°è À¯º´·üÀº 0.5%-2%·Î, ¹é¹ÝÁõÀ» À¯¹ßÇÏ´Â ÇǺΠÁúȯÀÎ ¹é¹ÝÁõÀº À¯ÀüÀû ¼ÒÀÎ, ÀÚ°¡¸é¿ªÁúȯ, ȯ°æÀû ¿äÀÎ µîÀÌ ¹é¹ÝÁõ À¯º´·ü Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. À¯·´, ÀϺ», ¹Ì±¹¿¡¼­ ½Ç½ÃµÈ Á¶»ç¿¡¼­ 18¼¼ ÀÌ»ó 35,694¸íÀÌ Âü¿©ÇßÀ¸¸ç, Àüü ¹é¹ÝÁõ À¯º´·üÀº 1.3%·Î ³ªÅ¸³µ½À´Ï´Ù. À¯·´ÀÌ °¡Àå ³ô¾Ò°í(1.6%), ¹Ì±¹(1.4%), ÀϺ»(0.5%)ÀÌ ±× µÚ¸¦ À̾ú½À´Ï´Ù. ¹é¹ÝÁõ Áõ»óÀ» ÀÎÁöÇÑ ÀÀ´äÀÚ 352¸í Áß 62.2%°¡ Á¤½Ä Áø´ÜÀ» ¹Þ¾ÒÀ¸¸ç, ¸ðµç Áö¿ª¿¡¼­ ÇǺΰú Àü¹®ÀÇ¿¡ ÀÇÇÑ Áø´ÜÀÌ ¿ì¼¼Çß½À´Ï´Ù. Áø´ÜÀ» ¹ÞÀº ȯÀÚÀÇ ´ëºÎºÐÀº 45¼¼ ¹Ì¸¸, ¿©¼º, ¹éÀÎÀ̾úÀ¸¸ç, 89.5%°¡ Ä¡·á °æÇèÀÌ ÀÖ´Ù°í ´äÇß½À´Ï´Ù. ÀÌ ¼±±¸ÀûÀÎ ¿¬±¸´Â ´Ù¾çÇÑ Àα¸ Áý´Ü¿¡¼­ ¹é¹ÝÁõÀÇ À¯º´·ü°ú Àα¸ Åë°è¿¡ ´ëÇÑ ±ÍÁßÇÑ ÀλçÀÌÆ®À» Á¦°øÇÕ´Ï´Ù. ±× °á°ú, ³ôÀº ¹é¹ÝÁõ À¯º´·üÀº ½ÃÀå ¼ºÀåÀ» Áö¿øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ÁöÁöÀûÀÎ ÀÇ·á Á¤Ã¥, ÀÇ·áºñ ÁöÃâ Áõ°¡, ÀÇ·áºñ ÁöÃâ Áõ°¡´Â ½ÃÀå¿¡ À¯¸®ÇÑ ±âȸ¸¦ âÃâÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª °áÁ¤ÀûÀÎ Ä¡·á¹ýÀÇ ºÎÁ·°ú ³ôÀº Ä¡·á ºñ¿ëÀº 2023-2030³âÀÇ ¿¹Ãø ±â°£ Áß ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°èÀÇ ¹é¹ÝÁõ Ä¡·á ½ÃÀå Á¶»ç¿¡¼­ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÔ´Ï´Ù. ºÏ¹Ì´Â ¹é¹ÝÁõ »ç·Ê Áõ°¡, Ä¡·á ±â¼ú ¹ßÀü, ¹é¹ÝÁõ¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡·Î ÀÎÇØ 2022³â ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. ¹Ý¸é, ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¹é¹ÝÁõ À¯º´·ü Áõ°¡, ÀÇ·áºñ ÁöÃâ Áõ°¡, ÀÏ¹Ý Àα¸¿Í ÀÇ·á Àü¹®°¡ ¸ðµÎ¿¡¼­ ¹é¹ÝÁõÀ» Æ÷ÇÔÇÑ ÇǺΠÁúȯ¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¿¹Ãø ±â°£ Áß °¡Àå ºü¸¥ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º» Á¶»çÀÇ ¸ñÀûÀº ÃÖ±ÙÀÇ ´Ù¾çÇÑ ºÎ¹® ¹× ±¹°¡ ½ÃÀå ±Ô¸ð¸¦ Á¤ÀÇÇϰí, ÇâÈÄ ¼ö³â°£ ½ÃÀå ±Ô¸ð¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. Á¶»ç ´ë»ó±¹¿¡¼­ »ê¾÷ÀÇ ÁúÀû¡¤¾çÀû Ãø¸é ¾çÃøÀ» Æ÷ÇÔ½Ã۵µ·Ï ¼³°èµÇ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ ½ÃÀåÀÇ ¹Ì·¡Àû ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀÎ ¹× °úÁ¦ µîÀÇ Áß¿äÇÑ Ãø¸é¿¡ °üÇÑ »ó¼¼ Á¤º¸µµ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ±â¾÷ÀÇ °æÀï ±¸µµ ¹× Á¦Ç° Á¦°øÀÇ »ó¼¼ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚ°¡ ÅõÀÚÇϱâ À§ÇÑ ¹Ì½ÃÀû ½ÃÀå¿¡¼­ÀÇ ÀáÀçÀû ±âȸµµ Æ÷ÇÔÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼¼°èÀÇ ¹é¹ÝÁõ Ä¡·á ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§

  • Á¶»ç ¸ñÀû
  • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
    • »ê¾÷ÀÇ ÁøÈ­
    • Á¶»ç ¹üÀ§
  • Á¶»ç ´ë»ó³â
  • ÅëÈ­ ȯ»êÀ²

Á¦3Àå ¼¼°èÀÇ ¹é¹ÝÁõ Ä¡·á ½ÃÀå ¿ªÇÐ

  • ¹é¹ÝÁõ Ä¡·áÁ¦ ½ÃÀåÀÇ ¿µÇ⠺м®(2020-2030³â)
    • ½ÃÀå ÃËÁø¿äÀÎ
      • ¹é¹ÝÀÇ À¯º´·ü Áõ°¡
      • ¹Ì¿ë Ä¡·á¿¡ ´ëÇÑ È¯ÀÚÀÇ ¼ö¿ä Áõ°¡
      • ¹é¹Ý°ú Ä¡·á¹ý¿¡ °üÇÑ ÀÎÁöµµÀÇ Çâ»ó
    • ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
      • °áÁ¤ÀûÀÎ Ä¡·á¹ýÀÇ °á¿©
      • ³ôÀº Ä¡·áºñ
    • ½ÃÀå ±âȸ
      • ÁöÁöÀû ÇコÄɾî Á¤Ã¥°ú Áø·á º¸¼ö
      • ÀÇ·áºñÀÇ Áõ°¡

Á¦4Àå ¼¼°èÀÇ ¹é¹ÝÁõ Ä¡·á ½ÃÀå »ê¾÷ ºÐ¼®

  • Porter's Five Forces ¸ðµ¨
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ±¸¸ÅÀÚÀÇ ±³¼··Â
    • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°è
  • Porter's Five Forces ¿µÇ⠺м®
  • PEST ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ȯ°æ
    • ¹ý·ü
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«
  • COVID-19 ¿µÇ⠺м®
  • ÆÄ±«Àû µ¿Çâ
  • ¾÷°è Àü¹®°¡ÀÇ ½ÃÁ¡
  • ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð¡¤Á¦¾È

Á¦5Àå ¼¼°èÀÇ ¹é¹ÝÁõ Ä¡·á ½ÃÀå : À¯Çüº°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ ¹é¹ÝÁõ Ä¡·á ½ÃÀå : À¯Çüº° ½ÇÀû - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ ¹é¹ÝÁõ Ä¡·á ½ÃÀå : À¯Çüº° ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
  • ¹é¹ÝÁõ Ä¡·á ½ÃÀå : ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • ºÎ¹®º°
    • ºñºÎ¹®

Á¦6Àå ¼¼°èÀÇ ¹é¹ÝÁõ Ä¡·á ½ÃÀå : À¯Åë ä³Îº°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ ¹é¹ÝÁõ Ä¡·á ½ÃÀå : À¯Åë ä³Îº°, ½ÇÀû - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ ¹é¹ÝÁõ Ä¡·á ½ÃÀå : À¯Åë ä³Îº° ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
  • ¹é¹ÝÁõ Ä¡·á ½ÃÀå : ÇÏÀ§ ºÎ¹® ºÐ¼®
    • µå·¯±×½ºÅä¾î¿Í ¼Ò¸Å ¾à±¹
    • ¿Â¶óÀÎ ÇÁ·Î¹ÙÀÌ´õ
    • º´¿ø ¾à±¹

Á¦7Àå ¼¼°èÀÇ ¹é¹ÝÁõ Ä¡·á ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ ¹é¹ÝÁõ Ä¡·á ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº°, ½ÇÀû - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ ¹é¹ÝÁõ Ä¡·á ½ÃÀå : ¾àÁ¦ Ŭ·¡½ºº° ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
  • ¹é¹ÝÁõ Ä¡·áÁ¦ ½ÃÀå : ÇÏÀ§ ºÎ¹® ºÐ¼®
    • ºÎ½ÅÇÇÁú ½ºÅ×·ÎÀ̵å
    • Ä®½Ã´º¸° ÀúÇØÁ¦
    • ±âŸ

Á¦8Àå ¼¼°èÀÇ ¹é¹ÝÁõ Ä¡·á ½ÃÀå : Áö¿ªº° ºÐ¼®

  • ÁÖ¿ä ±¹°¡
  • ÁÖ¿ä ½ÅÈï ±¹°¡
  • ¹é¹ÝÁõ Ä¡·áÁ¦ ½ÃÀå, Áö¿ªº° ½ÃÀå ½º³À¼ô
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´ÀÇ ¹é¹ÝÁõ Ä¡·á ½ÃÀå ½º³À¼ô
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¹é¹ÝÁõ Ä¡·á ½ÃÀå ½º³À¼ô
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ¹é¹ÝÁõ Ä¡·á ½ÃÀå ½º³À¼ô
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå °æÀï Á¤º¸

  • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®
  • ÁÖ¿ä ½ÃÀå Àü·«
  • ±â¾÷ °³¿ä
    • Clinuvel Pharmaceuticals Ltd.
    • Bausch Health Companies Inc.
    • Belcher Pharmaceuticals, LCC
    • Dr. Reddy's Laboratories Ltd.
    • Glenmark Pharmaceuticals Ltd.
    • Astellas Pharma Inc.
    • Pfizer Inc.
    • Strides Pharma Science Limited
    • Arcutis Biotherapeutics, Inc
    • Panacea Biotec Ltd.

Á¦10Àå Á¶»ç ÇÁ·Î¼¼½º

  • Á¶»ç ÇÁ·Î¼¼½º
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • ºÐ¼®
    • ½ÃÀå ÃßÁ¤
    • °ËÁõ
    • ÃâÆÇ
  • Á¶»ç ¼Ó¼º
  • Á¶»ç ÀüÁ¦Á¶°Ç
KSA 24.04.04

Global Vitiligo Treatment Market is valued at approximately USD 446.56 million in 2022 and is anticipated to grow with a healthy growth rate of more than 4.3% during the forecast period 2023-2030. Vitiligo is a skin disorder characterized by the loss of pigment-producing cells (melanocytes), leading to the development of white patches on the skin. While there is currently no cure for vitiligo, various treatments aim to manage and control the condition. The choice of treatment depends on factors such as the extent of depigmentation, the patient's age, and overall health. The key factors driving the market growth are the increasing prevalence of vitiligo, rising patient demand for aesthetic treatments, and increasing awareness about vitiligo and its available treatments that anticipated to create a lucrative demand for the market during the forecast period 2023-2030.

Additionally, A rising incidence of vitiligo worldwide contributes to the demand for effective treatments. Factors such as genetic predisposition, autoimmune disorders, and environmental factors contribute to the increasing prevalence of vitiligo. According to the Journal of the American Academy of Dermatology, the global prevalence of vitiligo, a skin condition causing white patches, ranges from 0.5% to 2%. A survey across Europe, Japan, and the United States involved 35,694 participants aged 18 and above, revealing an overall vitiligo prevalence of 1.3%. Europe had the highest prevalence (1.6%), followed by the US (1.4%) and Japan (0.5%). Of 352 respondents aware of vitiligo signs, 62.2% received a formal diagnosis, with dermatologists predominantly diagnosing in all regions. Most diagnosed patients were under 45, female, and Caucasian. 89.5% reported previous treatments. This pioneering study provides valuable insights into vitiligo prevalence and demographics across diverse populations. As a result, the higher prevalence of vitiligo is anticipated to support the market growth. Moreover, supportive healthcare policies and reimbursement, and increasing healthcare expenditure are anticipated to create lucrative opportunities for the market. However, the lack of a definitive cure and high treatment costs stifle market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Vitiligo Treatment Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the rising incidence of vitiligo cases, advancements in treatment technologies, and increased awareness about vitiligo. Whereas, the Asia Pacific is expected to grow at the fastest growth rate over the forecast period, owing to factors such as the increasing prevalence of vitiligo, growing healthcare spending, and rising awareness about skin disorders, including vitiligo, among both the general population and healthcare professionals.

Major market player included in this report are:

  • Clinuvel Pharmaceuticals Ltd.
  • Bausch Health Companies Inc.
  • Belcher Pharmaceuticals, LCC
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Astellas Pharma Inc.
  • Pfizer Inc.
  • Strides Pharma Science Limited
  • Arcutis Biotherapeutics, Inc
  • Panacea Biotec Ltd.

Recent Developments in the Market:

  • In Mar 2022, STRATA Skin Sciences, a pioneering medical technology company focused on advancing innovative solutions for autoimmune skin conditions, recently revealed its collaboration with the Global Vitiligo Foundation (GVF) as a corporate sponsor. The partnership underscores STRATA's commitment to developing, bringing to market, and promoting cutting-edge products for the effective treatment of diverse autoimmune skin diseases.

Global Vitiligo Treatment Market Report Scope:

  • Historical Data - 2020 - 2021
  • Base Year for Estimation - 2022
  • Forecast period - 2023-2030
  • Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered - Type, Distribution Channel, Drug Class Type, Region
  • Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:

  • Segmental
  • Non-Segmental

By Distribution Channel:

  • Drug Stores and Retail Pharmacies
  • Online Providers
  • Hospital Pharmacies

By Drug Class Type:

  • Corticosteroids
  • Calcineurin Inhibitor
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Million)
    • 1.2.1. Vitiligo Treatment Market, by Region, 2020-2030 (USD Million)
    • 1.2.2. Vitiligo Treatment Market, by Type, 2020-2030 (USD Million)
    • 1.2.3. Vitiligo Treatment Market, by Distribution Channel, 2020-2030 (USD Million)
    • 1.2.4. Vitiligo Treatment Market, by Drug Class Type, 2020-2030 (USD Million)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Vitiligo Treatment Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Vitiligo Treatment Market Dynamics

  • 3.1. Vitiligo Treatment Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing prevalence of vitiligo
      • 3.1.1.2. Rising patient demand for aesthetic treatments
      • 3.1.1.3. Increasing awareness about vitiligo and its available treatments
    • 3.1.2. Market Challenges
      • 3.1.2.1. Lack of a definitive cure
      • 3.1.2.2. High treatment costs
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Supportive healthcare policies and reimbursement
      • 3.1.3.2. Increasing healthcare expenditure

Chapter 4. Global Vitiligo Treatment Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Vitiligo Treatment Market, by Type

  • 5.1. Market Snapshot
  • 5.2. Global Vitiligo Treatment Market by Type, Performance - Potential Analysis
  • 5.3. Global Vitiligo Treatment Market Estimates & Forecasts by Type 2020-2030 (USD Million)
  • 5.4. Vitiligo Treatment Market, Sub Segment Analysis
    • 5.4.1. Segmental
    • 5.4.2. Non-Segmental

Chapter 6. Global Vitiligo Treatment Market, by Distribution Channel

  • 6.1. Market Snapshot
  • 6.2. Global Vitiligo Treatment Market by Distribution Channel, Performance - Potential Analysis
  • 6.3. Global Vitiligo Treatment Market Estimates & Forecasts by Distribution Channel 2020-2030 (USD Million)
  • 6.4. Vitiligo Treatment Market, Sub Segment Analysis
    • 6.4.1. Drug Stores and Retail Pharmacies
    • 6.4.2. Online Providers
    • 6.4.3. Hospital Pharmacies

Chapter 7. Global Vitiligo Treatment Market, by Drug Class Type

  • 7.1. Market Snapshot
  • 7.2. Global Vitiligo Treatment Market by Drug Class Type, Performance - Potential Analysis
  • 7.3. Global Vitiligo Treatment Market Estimates & Forecasts by Drug Class Type 2020-2030 (USD Million)
  • 7.4. Vitiligo Treatment Market, Sub Segment Analysis
    • 7.4.1. Corticosteroids
    • 7.4.2. Calcineurin Inhibitor
    • 7.4.3. Others

Chapter 8. Global Vitiligo Treatment Market, Regional Analysis

  • 8.1. Top Leading Countries
  • 8.2. Top Emerging Countries
  • 8.3. Vitiligo Treatment Market, Regional Market Snapshot
  • 8.4. North America Vitiligo Treatment Market
    • 8.4.1. U.S. Vitiligo Treatment Market
      • 8.4.1.1. Type breakdown estimates & forecasts, 2020-2030
      • 8.4.1.2. Distribution Channel breakdown estimates & forecasts, 2020-2030
      • 8.4.1.3. Drug Class Type breakdown estimates & forecasts, 2020-2030
    • 8.4.2. Canada Vitiligo Treatment Market
  • 8.5. Europe Vitiligo Treatment Market Snapshot
    • 8.5.1. U.K. Vitiligo Treatment Market
    • 8.5.2. Germany Vitiligo Treatment Market
    • 8.5.3. France Vitiligo Treatment Market
    • 8.5.4. Spain Vitiligo Treatment Market
    • 8.5.5. Italy Vitiligo Treatment Market
    • 8.5.6. Rest of Europe Vitiligo Treatment Market
  • 8.6. Asia-Pacific Vitiligo Treatment Market Snapshot
    • 8.6.1. China Vitiligo Treatment Market
    • 8.6.2. India Vitiligo Treatment Market
    • 8.6.3. Japan Vitiligo Treatment Market
    • 8.6.4. Australia Vitiligo Treatment Market
    • 8.6.5. South Korea Vitiligo Treatment Market
    • 8.6.6. Rest of Asia Pacific Vitiligo Treatment Market
  • 8.7. Latin America Vitiligo Treatment Market Snapshot
    • 8.7.1. Brazil Vitiligo Treatment Market
    • 8.7.2. Mexico Vitiligo Treatment Market
  • 8.8. Middle East & Africa Vitiligo Treatment Market
    • 8.8.1. Saudi Arabia Vitiligo Treatment Market
    • 8.8.2. South Africa Vitiligo Treatment Market
    • 8.8.3. Rest of Middle East & Africa Vitiligo Treatment Market

Chapter 9. Competitive Intelligence

  • 9.1. Key Company SWOT Analysis
    • 9.1.1. Company 1
    • 9.1.2. Company 2
    • 9.1.3. Company 3
  • 9.2. Top Market Strategies
  • 9.3. Company Profiles
    • 9.3.1. Clinuvel Pharmaceuticals Ltd.
      • 9.3.1.1. Key Information
      • 9.3.1.2. Overview
      • 9.3.1.3. Financial (Subject to Data Availability)
      • 9.3.1.4. Product Summary
      • 9.3.1.5. Recent Developments
    • 9.3.2. Bausch Health Companies Inc.
    • 9.3.3. Belcher Pharmaceuticals, LCC
    • 9.3.4. Dr. Reddy's Laboratories Ltd.
    • 9.3.5. Glenmark Pharmaceuticals Ltd.
    • 9.3.6. Astellas Pharma Inc.
    • 9.3.7. Pfizer Inc.
    • 9.3.8. Strides Pharma Science Limited
    • 9.3.9. Arcutis Biotherapeutics, Inc
    • 9.3.10. Panacea Biotec Ltd.

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦